The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study
Autor: | Val Gebski, Ronald Cw Ma, Rachel O'Connell, Weiping Jia, Andrzej S. Januszewski, Kwok Leung Ong, David R. Sullivan, Kerry-Anne Rye, Anthony C Keech, Russell S. Scott, Alicia J. Jenkins, Aimin Xu, Liang Wu, Liping Li, Huating Li |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
0301 basic medicine medicine.medical_specialty Time Factors Myeloblastin serine protease Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Type 2 diabetes Gastroenterology 03 medical and health sciences 0302 clinical medicine Fenofibrate Proteinase 3 Intervention (counseling) Diabetes mellitus Internal medicine Internal Medicine medicine Humans cardiovascular diseases Aged Hypolipidemic Agents Inflammation biomarkers diabetes biology business.industry Middle Aged Cardiovascular disease medicine.disease Lipids microvascular disease proteinase 3 Treatment Outcome 030104 developmental biology Diabetes Mellitus Type 2 Neutrophil elastase biology.protein Biomarker (medicine) Female Original Article Inflammation Mediators Leukocyte Elastase Cardiology and Cardiovascular Medicine business neutrophil elastase Biomarkers medicine.drug |
Zdroj: | Diabetes & Vascular Disease Research |
ISSN: | 1752-8984 1479-1641 |
Popis: | Introduction: Neutrophil elastase (NE) and proteinase 3 (PR3) are novel inflammation biomarkers. We investigated their associations with chronic complications, determinants of biomarker levels and effects of fenofibrate in patients with type 2 diabetes mellitus (T2DM) from Fenofibrate Intervention and Event Lowering in Diabetes study. Methods: Plasma NE and PR3 levels were quantified at baseline ( n = 2000), and relationships with complications over 5-years assessed. Effects of fenofibrate on biomarker levels ( n = 200) were determined at four follow-up visits. Results: Higher waist-to-hip ratio, homocysteine and C-reactive protein and lower apoA-II were determinants of higher NE and PR3 levels. Higher NE levels were associated with on-trial stroke and cardiovascular mortality, and higher PR3 levels with on-trial stroke, but associations were not significant after adjustment for confounding factors. Although higher NE and PR3 levels were associated with baseline total microvascular disease, only NE levels were associated with on-trial neuropathy or amputation. These associations were not significant after adjusting for multiple comparisons. NE and PR3 levels did not change with fenofibrate. Conclusions: In T2DM plasma NE and PR3 levels are associated with vascular risk factors, and total microvascular disease at baseline, but on rigorous analyses were not associated with on-trial complications. Levels were not changed by fenofibrate. |
Databáze: | OpenAIRE |
Externí odkaz: |